Result:Steady· Market: Flat#One-off gain#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 0.00 | ||
| Total Income | 5.11 | 38.2% | 212.6% |
| Expenditure | 0.76 | 42.0% | 167.4% |
| PBT | 4.35 | 82.3% | 222.1% |
| Net Profit | 3.42 | 63.4% | 244.4% |
| OPM | — | ||
| NPM | 66.90% | 10.34pp | 6.18pp |
| EPS | 2.79 | 63.2% | 244.4% |
Zero core pharma revenue in both periods — the entire PAT rise is non-operating other income off a small prior-year base, so it's non-core driven and capped mid-band despite the large YoY jump.
Informational and educational content only. Not investment advice.